Nicotinic receptors and mental illness

Nicotinic Receptors

Volumn , Issue , 2014, Pages 417-434

  Leonard, Sherry ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 7; CHRFAM7A; CHRNA7; Gene duplication; Nicotinic receptor; Schizophrenia; Smoking

Indexed keywords

EID: 84932192816     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1167-7_20     Document Type: Chapter

References (158)

1. NIMH. The numbers count: mental disorders in America. Bethesda, MD: NIH; 2013.
2. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nic Tob Res. 2008;10:1691-715.
3. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, et al. Smoking and mental illness. Pharmacol Biochem Behav. 2001;70:561-70.
4. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness -a population-based prevalence study. JAMA. 2000;284(20):2606-10.
5. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory fi ndings. Am J Psychiatry. 1998;155:1490-501.
6. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schiz Res. 2005;76:135-57.
7. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Add Behav. 2004;29:1067-83.
8. Leonard S, Gault J, Adams C, Breese CR, Rollins Y, Adler LE, et al. Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci. 1998;12:195-201.
9. Aubin HJ, Rollema H, Svensson RH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36:271-84.
10. Williams JM, Gandhi KK, Lu SE, Kumar S, Shen JW, Foulds J, et al. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nic Tob Res. 2010;12:855-9.
11. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42:1-5.
12. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schiz Res. 2005;79:323-35.
13. Williams JM, Gandhi KK, Lu SE, Kumar S, Steinberg ML, Cottler B, et al. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug Alc Depend. 2011;118:313-9.
14. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alc Depend. 2005;80:259-65.
15. Williams JM, Gandhi KK, Lu SE, Steinberg ML, Benowitz NL. Rapid smoking may not be aversive in schizophrenia. Nic Tob Res. 2013;15:262-6.
16. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. JAMA. 1990;264:1546-9.
17. Thornton LK, Baker AL, Lewin TJ, Kay-Lambkin FJ, Kavanagh D, Richmond R, et al. Reasons for substance use among people with mental disorders. Addict Behav. 2012;37:1134-43.
18. Janowsky DS, El-Yousef MK, David JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;2:632-5.
19. Janowsky DS, El-Yousef MK, David JM. Acetylcholine and depression. Psychosom Med. 1974;36:248-57.
20. Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, et al. Persistent beta(2)*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry. 2012;169:851-9.
21. Brasic JR, Cascella N, Kumar A, Zhou Y, Hilton J, Raymont V, et al. Positron emission tomography experience with 2-[ 18 F]fl uoro-3-(2(s)-azetidinylmethoxy)pyridine (2-[ 18 F]fa) in the living human brain of smokers with paranoid schizophrenia. Synapse. 2012;66:352-68.
22. D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, et al. Lower beta(2)*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry. 2012;169:326-34.
23. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem. 1999;72:1117-24.
24. Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety-and depressionlike behavior. Proc Natl Acad Sci. 2013;110:3573-8.
25. Brunzell DH, McIntosh JM. Alphα7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology. 2012;37:1134-43.
26. Leonard S, Mexal S, Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J Dual Diag. 2007;3:43-59.
27. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev. 2005;29:1021-34.
28. Forchuk C, Norman R, Malla A, Martin ML, McLean T, Cheng S, et al. Schizophrenia and the motivation for smoking. Perspect Psychiatry Care. 2002;38:41-9.
29. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856-61.
30. Cadenhead KS, Geyer MA, Swerdlow NR, Shafer K, Diaz M, Clementz BA, et al. Sensorimotor gating defi cits in schizophrenic patients and their relatives. Biol Psychiatry. 1998;43:33.
31. Freedman R, Waldo M, Bickford-Wimer P, Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schiz Res. 1991;4:233-43.
32. Clementz BA, Geyer MA, Braff DL. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schiz Res. 1998;30:71-80.
33. Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK. The effects of nicotine on specifi c eye tracking measures in schizophrenia. Biol Psychiatry. 2002;52:721-8.
34. Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res. 2003;117:223-36.
35. Tanabe J, Tregellas JR, Martin LF, Freedman R. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biol Psychiatry. 2006;59:754-61.
36. Kumari V, Soni W, Sharma T. Infl uence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum Psychopharmacol Clin Exp. 2001;16:321-6.
37. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacolgy. 2002;26(1):75-85.
38. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, et al. Effects of cigarette smoking on spatial working memory and attentional defi cits in schizophrenia -involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005;62(6):649-59.
39. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55(8):850-8.
40. Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology. 2004; 174(3):334-40.
41. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 1999;21(2):195-202.
42. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacolgy. 2002;27(3):479-97.
43. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206-27.
44. Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry. 2003; 8(3):255-6.
45. Dickinson JA, Kew JNC, Wonnacott S. Presynaptic alpha 7-and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol. 2008;74(2):348-59.
46. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol. 2000;393(1-3):51-8.
47. Covernton POJ, Lester RAJ. Prolonged stimulation of presynaptic nicotinic acetylcholine receptors in the rat interpeduncular nucleus has differential effects on transmitter release. Int J Develop Neurosci. 2002;20(3-5):247-58.
48. Schilstrom B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH. Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol. 2003;6(1):1-11.
49. Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R, et al. Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Mol Brain Res. 2005;139(2):317-32.
50. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nic Tob Res. 2008;10:1047-56.
51. Moss TG, Sacco KA, Alien RM, Weinberger AH, Vessicchio JC, George TP. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alc Depend. 2009;104:94-9.
52. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei XL, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165(9):1163-71.
53. Saccone NL, Schwantes-An TH, Wang JC, Grucza RA, Breslau N, Hatsukami D, et al. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 2010;9(7):741-50.
54. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008; 13(4):368-73.
55. Jackson KJ, Fanous AH, Chen J, Kendler KS, Chen X. Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder. Psychiatry Genet. 2013;23:20-8.
56. Chen LS, Xian H, Grucza RA, Saccone NL, Wang JC, Johnson EO, et al. Nicotine dependence and comorbid psychiatric disorders: examination of specifi c genetic variants in the CHRNA5-A3-B4 nicotinic receptor genes. Drug Alc Depend. 2012;123:S42-51.
57. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, Valle D, et al. Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet. 2003;73(3):601-11.
58. Freedman R, Leonard S, Olincy A, Kaufmann CA, Malaspina D, Cloninger CR, et al. Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet. 2001;105(8):794-800.
59. Gejman PV, Sanders AR, Badner JA, Cao QH, Zhang J. Linkage analysis of schizophrenia to chromosome 15. Am J Med Genet. 2001;105(8):789-93.
60. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, et al. NIMH Genetics Initiative Millennium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet. 1998;81(4):282-9.
61. Liu CM, Hwu HG, Lin MW, Ou-Yang WC, Lee SFC, Fann CSJ, et al. Suggestive evidence for linkage of schizophrenia to markers at chromosome 15q13-14 in Taiwanese families. Am J Med Genet. 2001;105(8):658-61.
62. Leonard S, Freedman R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry. 2006;60(2):115-22.
63. Riley BP, Makoff AM, Magudi-Carter M, Jenkins TJ, Williamson R, Collier DA, et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet. 2000;96:196-201.
64. Tsuang DW, Skol AD, Faraone SV, Bingham S, Young KA, Prabhudesai S, et al. Examination of genetic linkage of chromosome 15 to schizophrenia in a large veterans affairs cooperative study sample. Am J Med Genet. 2001;105(8):662-8.
65. Turecki G, Grof P, Grof E, D'Souza V, Cavazzoni P, Duffy A, et al. A genome scan using a pharmacogenetic approach indicates a susceptibility locus for BD on 15q14. Biol Psychiatry. 2000;47:69S.
66. Edenberg HJ, Foroud T, Conneally PM, Sorbel JJ, Carr K, Crose C, et al. Initial genomic scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 3, 5, 15, 16, 17, and 22. Am J Med Genet. 1997;74(3):238-46.
67. Stefansson H, Rujescu D, Cichon S, Pietilainen OPH, Ingason A, Steinberg S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455(7210):232-7.
68. Stone JL, O'Donovan MC, Gurling H, Kirov GK, Blackwood DHR, Corvin A, et al. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237-41.
69. Masurel-Paulet A, Andrieux J, Callier P, Cuisset JM, Le Caignec C, Holder M, et al. Delineation of 15q13.3 microdeletions. Clin Genet. 2010;78:149-61.
70. Miller DT, Shen Y, Weiss LA, Korn J, Anselm I, Bridgemohan C, et al. Microdeletion/ duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet. 2009;46(4):242-8.
71. Mewborn SK, Miley NL, Fantes JA, Brown RL, Butler MG, Christian SL, et al. Breakpoint junction fragments in Prader-Willi and Angelman syndrome (PWS/AS) deletion patients reveal variable breakpoints within large duplicons. Am J Hum Genet. 2002;71(4):736.
72. Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D. Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet. 2002;359(9301):135-6.
73. Vogels A, De Hert M, Descheemaeker MJ, Govers V, Devriendt K, Legius E, et al. Psychotic disorders in Prader-Willi syndrome. Am J Med Genet A. 2004;127A(3):238-43.
74. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, et al. Impaired attention is central to the cognitive defi cits observed in alpha 7 defi cient mice. Eur Neuropsychopharmacol. 2007;17(2):145-55.
75. Young JW, Meves JM, Tarantino IS, Caldwell S, Geyer MA. Delayed procedural learning in alpha 7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011;10:720-33.
76. Stevens KE, Adams CE, Yonchek J, Zheng L, Collins AC. C3H alphα7 nicotinic receptor heterozygote mice as a new model of schizophrenia. Schiz Res. 2010;117(2-3):510.
77. De Luca V, Wong AHC, Muller DJ, Wong GWH, Tyndale RF, Kennedy JL. Evidence of association between smoking and alpha 7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacolgy. 2004;29(8):1522-6.
78. Faraone SV, Su J, Taylor L, Wilcox M. A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Hum Hered. 2004;57(2):59-68.
79. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, et al. Effect of smoking history on [ 3 H]nicotine binding in human postmortem brain. J Pharm Exp Ther. 1997; 282:7-13.
80. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharm Exp Ther. 1999;289(3):1545-52.
81. Benwell ME, Balfour DJ, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[ 3 H]nicotine binding sites in human brain. J Neurochem. 1988;50(4):1243-7.
82. Benhammou K, Lee MJ, Strook M, Sullivan B, Logel J, Raschen K, et al. [ 3 H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day. Neuropharmacology. 2000;39:2818-29.
83. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, et al. Abnormal regulation of high affi nity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacolgy. 2000;23(4):351-64.
84. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995; 38(1):22-33.
85. Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic receptor alphα7 subunit in the frontal cortex from schizophrenic brain. Neuroreport. 1999;10(8): 1779-82.
86. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat. 2001;22(1-2):115-26.
87. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999;73(4):1590-7.
88. Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J, et al. Genomic organization and partial duplication of the human α7 neuronal nicotinic acetylcholine receptor gene. Genomics. 1998;52(2):173-85.
89. Riley B, Williamson M, Collier D, Wilkie H, Makoff A. A 3-Mb map of a large segmental duplication overlapping the alpha 7-nicotinic acetylcholine receptor gene ( CHRNA7 ) at human 15q13-q14. Genomics. 2002;79(2):197-209.
90. Locke DP, Jiang Z, Pertz LM, Misceo D, Archidiacono N, Eichler EE. Molecular evolution of the human chromosome 15 pericentromeric region. Cytogen Genome Res. 2005; 108(1-3):73-82.
91. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, et al. Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory defi cit found in schizophrenia. Arch Gen Psychiatry. 2002;59(12):1085-96.
92. Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. Genetics. 2000;156:297-304.
93. Houy E, Raux G, Thibaut F, Belmont A, Demily C, Allio G, et al. The promoter-194 C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating defi cit. Mol Psychiatry. 2004;9(3):320-2.
94. Stephens SH, Franks A, Berger R, Palionyte M, Fingerlin TE, Wagner B, et al. Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. Psychiatric Genetics. 2012;22:1-14.
95. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry. 2010;69:7-11.
96. Kem WR, Mahnir VM, Prokai L, Papke RL, Cao XF, LeFrancois S, et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol. 2004;65(1):56-67.
97. Ross RG, Hunter SK, McCarthy L, Beuler J, Hutchison AK, Wagner BD, et al. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am J Psychiatry. 2013;170:290-8.
98. Gault J, Hopkins J, Berger R, Drebing C, Logel J, Walton K, et al. Comparison of polymorphisms in the α7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am J Med Genet B. 2003;123(1):39-49.
99. Sinkus ML, Lee MJ, Gault J, Logel J, Short M, Freedman R, et al. A 2-base pair deletion polymorphism in the partial duplication of the alpha 7 nicotinic acetylcholine gene ( CHRFAM7A ) on chromosome 15q14 is associated with schizophrenia. Brain Res. 2009;1291:1-11.
100. Raux G, Bonnet-Brilhault F, Louchart S, Houy E, Gantier R, Levillain D, et al. The-2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating defi cit. Mol Psychiatry. 2002;7(9):1006-11.
101. Flomen RH, Shaikh M, Walshe M, Schulze K, Hall M-H, Picchioni M, et al. Association between the 2-bp deletion polymorphism in the duplicated version of the alphα7 nicotinic receptor gene and P50 gating. Eur J Hum Genet. 2013;21:76-81.
102. Flomen RH, Davies AF, Di Forti M, La Cascia C, Mackie-Ogilvie C, Murray R, et al. The copy number variant involving part of the alpha 7 nicotinic receptor gene contains a polymorphic inversion. Eur J Hum Genet. 2008;16(11):1364-71.
103. Villiger Y, Szanto I, Jaconi S, Blanchet C, Buisson B, Krause KH, et al. Expression of an alpha 7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J Neuroimmunol. 2002;126(1-2):86-98.
104. Araud T, Graw S, Berger R, Neveu E, Bertrand D, Leonard S. The duplicated alpha 7 nicotinic receptor gene CHRFAM7A is a dominant negative regulator of CHRNA7 expression. Biochem Pharmacol. 2011;82:904-14.
105. de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, Renart J, Atienza G, Serantes R, et al. Function of partially duplicated human alpha 7 nicotinic receptor subunit CHRFAM7A Gene: potential implications for the cholinergic anti-infl ammatory response. J Biol Chem. 2011; 286(1):594-606.
106. Benfante R, Antonini RA, De Pizzol M, Gotti C, Clementi F, Locati M, et al. Expression of the α7 nAChR subunit duplicate form ( CHRFAM7A ) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. J Immunol. 2011;230:74-84.
107. Gault J, Logel J, Drebing C, Berger R, Hopkins J, Olincy A, et al. Mutation analysis of the α7 nicotinic acetylcholine receptor gene and its partial duplication in schizophrenia patients. Am J Hum Genet. 1999;65(Supp.):A271.
108. Canastar A, Logel J, Graw S, Finlay-Schulz JF, Osborne C, Palionyte M, et al. DNA methylation and tissue-specifi c transcription of the α7 nicotinic receptor gene ( CHRNA7 ). J Mol Neurosci. 2012;47:389-400.
109. Finlay-Schulz JA, Canastar A, Short M, El Gazzar MA, Leonard S. Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene ( CHRNA7 ) by AP-2a. J Biol Chem. 2011;286:42123-32.
110. Stevens KE, Bullock AE, Collins AC. Chronic corticosterone treatment alters sensory gating in C3H mice. Pharmacol Biochem Behav. 2001;69(3-4):359-66.
111. Bullock AE, Clark AL, Grady SR, Robinson SF, Slobe BS, Marks MJ, et al. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem. 1997;68(6):2412-23.
112. Carrasco-Serrano C, Criado M. Glucocorticoid activation of the neuronal nicotinic acetylcholine receptor alpha 7 subunit gene: involvement of transcription factor Egr-1. FEBS Lett. 2004;566(1-3):247-50.
113. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. Ann Med. 2004;36(1):62-71.
114. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60(2):132-40.
115. Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry. 2005;10(4):366-74.
116. Yang X, Kuo YH, Devay P, Yu CR, Role L. A cysteine-rich isoform of neuregulin controls the level of expression of neuronal nicotinic receptor channels during synaptogenesis. Neuron. 1998;20(2):255-70.
117. Chen YJJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N, et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci. 2008;28(27):6872-83.
118. Mathew SV, Law AJ, Lipska BK, Davila-Garcia MI, Zamora ED, Mitkus SN, et al. Alpha 7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet. 2007;16(23):2921-32.
119. Hsu YN, Edwards SC, Wecker L. Nicotine enhances the cyclic AMP-dependent protein kinase-mediated phosphorylation of alpha 4 subunits of neuronal nicotinic receptors. J Neurochem. 1997;69(6):2427-31.
120. Moss SJ, McDonald BJ, Rudhard Y, Schoepfer R. Phosphorylation of the predicted major intracellular domains of the rat and chick neuronal nicotinic acetylcholine receptor alpha 7 subunit by cAMP-dependent protein kinase. Neuropharmacology. 1996;35(8):1023-8.
121. Drisdel RC, Manzana E, Green WN. The role of palmitoylation in functional expression of nicotinic alpha 7 receptors. J Neurosci. 2004;24(46):10502-10.
122. Alexander JK, Govind AP, Drisdel RC, Blanton MP, Vallejo Y, Lam TT, et al. Palmitoylation of nicotinic acetylcholine receptors. J Mol Neurosci. 2010;40:12-20.
123. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schiz Res. 2000;42(1):7-17.
124. Castelan F, Castillo M, Mulet J, Sala S, Sala F, del Toro ED, et al. Molecular characterization and localization of the RIC-3 protein, an effector of nicotinic acetylcholine receptor expression. J Neurochem. 2008;105(3):617-27.
125. Valles AS, Barrantes FJ. Chaperoning alpha 7 neuronal nicotinic acetylcholine receptors. Biochim Biophys Acta. 1818;2012:718-29.
126. Miwa JM, Stevens TR, King SL, Caldarone BJ, Ibanez-Tallon I, Cheng X, et al. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. Neuron. 2006;51(5):587-600.
127. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science. 2010;330(6008):1238-40.
128. Lester HA, Xiao C, Srinivasan R, Son CD, Miwa J, Pantoja R, et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry: implications for drug discovery. AAPS J. 2009;11(1):167-77.
129. Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AFT, Wang M. Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci. 2013;110(29):12078-83.
130. Levy RB, Aoki C. alpha 7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex. J Neurosci. 2002;22(12):5001-15.
131. Li S, Li ZX, Pei L, Le AD, Liu F. The α7nACh-NMDA rceptor complex is involved in cue-induced reinstatement of nicotine seeking. J Exp Med. 2012;209(12):2141-7.
132. Yasui DH, Scoles HA, Horike S, Meguro-Horike M, Dunaway KW, Schroeder DI, et al. 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with defi ciencies in Rett and autism brain. Hum Mol Genet. 2011;20(22):4311-23.
133. Green MF. What are the functional consequences of neurocognitive defi cits in schizophrenia. Am J Psychiatry. 1996;153:321-30.
134. Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000;31(2):131-44.
135. D'Souza MS, Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive defi cits. Neuropharmacology. 2012;62:1371-80.
136. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-10.
137. Lieberman JA, Stroup TS. The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry. 2011;168:770-5.
138. Barnes NM, Sharp T. A review of central 5HT receptors and their function. Neuropharmacology. 1999;38:1083-152.
139. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine effl ux in the hippocampus of the rat. Neuropsychopharmacolgy. 2002;26(5):583-94.
140. McEvoy J, Freudenreich O, McGee M, Vanderzwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37(8):550-2.
141. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schiz Bull. 1999;25(2):233-55.
142. Adler LE, Hoffer LJ, Griffi th J, Waldo MC, Freedman R. Normalization by nicotine of defi cient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 1992; 32:607-16.
143. Nagamoto HT, Adler LE, Hea RA, Griffi th JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry. 1996;40(3):181-8.
144. Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves defi cits in auditory P50 suppression in schizophrenia. Schiz Res. 2005;76(1):67-72.
145. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing C, et al. Effi cacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Int Med. 2006;166:1571-7.
146. Smith RC, Lindenmayer J-P, Davis JM, Cornwell J, Noth K, Gupta S, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schiz Res. 2009;110:149-55.
147. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and effi cacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:654-60.
148. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007; 164(8):1269.
149. Liu ME, Tsai SJ, Yang ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizophrenia. CNS Spect. 2009;14:346.
150. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(6):630-8.
151. Olincy A, Freedman R, Buchanan RW, Harris JG, Gold JM, Johnson LL, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040-7.
152. Stephens SH, Logel J, Barton A, Franks A, Schultz J, Short M, et al. Association of the 5'-upstream regulatory region of the α7 nicotinic acetylcholine receptor subunit gene ( CHRNA7 ) with schizophrenia. Schiz Res. 2009;109:102-12.
153. Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. Ann Rev Nutr. 2006;26:229-50.
154. Ross RG, Stevens KE, Proctor WR, Leonard S, Kisley MA, Hunter SK, et al. Cholinergic mechanisms, early brain development, and risk for schizophrenia. J Child Psychol Psychiatry. 2010;51:535-49.
155. Hunter SK, Corral N, Ponicsan H, Ross RG. Reliability of P50 auditory sensory gating measures in infants during active sleep. Neuroreport. 2008;19(1):79-82.
156. Liu ZP, Neff RA, Berg DK. Sequential interplay of nicotinic and GABAergic signaling guides neuronal development. Science. 2006;314:1610-3.
157. Arion D, Lewis DA. Altered expression of regulators of the cortical chloride transporters NRCC1 and KCC2 in schizophrenia. Arch Gen Psychiatry. 2010;68:21-31.
158. Bertrand D, Bertrand S, Cassar S, Gubbins E, Li JH, Gopalakrishnan M. Positive allosteric modulation of the alpha 7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol Pharmacol. 2008;74(5):1407-16.